Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies

Oral administration of Bruton's tyrosine kinase inhibitors impairs GPVI-mediated platelet function

(2016) Rachel A. Rigg et al.   AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY

The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis

(2016) Darryl P. Leong et al.   BLOOD

Antithrombotic Therapy for VTE Disease

(2016) Clive Kearon et al.   CHEST

Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling

(2016) L de Zwart et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor

(2016) Jingjing Wu et al.   Journal of Hematology & Oncology

Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment

(2016) Allison E. Burnett et al.   JOURNAL OF THROMBOSIS AND THROMBOLYSIS

Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial

(2016) M Irem Baharoglu et al.   LANCET

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

(2016) Martin Dreyling et al.   LANCET

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study

(2016) Asher Chanan-Khan et al.   LANCET ONCOLOGY

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura

(2016) Flora Peyvandi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

(2016) John C. Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

The VWF-GPIb axis in ischaemic stroke: lessons from animal models

(2016) Frederik Denorme et al.   THROMBOSIS AND HAEMOSTASIS

Ibrutinib Inhibits Platelet Integrin αIIbβ3Outside-In Signaling and Thrombus Stability But Not Adhesion to CollagenSignificance

(2015) Alexander P. Bye et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

C-type lectin like receptor 2 (CLEC-2) signals independently of lipid raft microdomains in platelets

(2015) Bhanu Kanth Manne et al.   BIOCHEMICAL PHARMACOLOGY

A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies

(2015) H. S. Walter et al.   BLOOD

Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib

(2015) J. C. Byrd et al.   BLOOD

Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results

(2015) M. L. Wang et al.   BLOOD

Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib

(2015) A. H. Lipsky et al.   HAEMATOLOGICA

Distinct Pathways Regulate Syk Protein Activation Downstream of Immune Tyrosine Activation Motif (ITAM) and hemITAM Receptors in Platelets

(2015) Bhanu Kanth Manne et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia

(2015) Steven P. Treon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

(2015) Jan A. Burger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib

(2015) A. H. Lipsky et al.   HAEMATOLOGICA

The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis

(2014) C. Chai-Adisaksopha et al.   BLOOD

Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions

(2014) M. Levade et al.   BLOOD

Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling

(2014) J. R. McMullen et al.   BLOOD

Bruton's Tyrosine Kinase: From X-Linked Agammaglobulinemia Toward Targeted Therapy for B-Cell Malignancies

(2014) Sabine Ponader et al.   JOURNAL OF CLINICAL ONCOLOGY

2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary

(2014) Craig T. January et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation

(2014) S Kamel et al.   LEUKEMIA

Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

(2014) John C. Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting Platelet GPIbβ Reduces Platelet Adhesion, GPIb Signaling and Thrombin Generation and Prevents Arterial Thrombosis

(2013) Eric Maurer et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial

(2013) Willem JM Dewilde et al.   LANCET

Podoplanin maintains high endothelial venule integrity by interacting with platelet CLEC-2

(2013) Brett H. Herzog et al.   NATURE

The physiological and pathophysiological roles of platelet CLEC-2

(2013) Stacey A. Langan et al.   THROMBOSIS AND HAEMOSTASIS

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

(2012) Ranjana H. Advani et al.   JOURNAL OF CLINICAL ONCOLOGY

The future of glycoprotein VI as an antithrombotic target

(2012) M. ZAHID et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Apixaban for Extended Treatment of Venous Thromboembolism

(2012) Giancarlo Agnelli et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Selective Serotonin Reuptake Inhibitors on Platelet Function

(2011) Francisco J. de Abajo   DRUGS & AGING

Genetic and antibody-induced glycoprotein VI deficiency equally protects mice from mechanically and FeCl3-induced thrombosis

(2011) M. BENDER et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

The evolution of antiplatelet therapy in cardiovascular disease

(2011) Omair Yousuf et al.   Nature Reviews Cardiology

Apixaban versus Warfarin in Patients with Atrial Fibrillation

(2011) Christopher B. Granger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparison of two murine models of thrombosis induced by atherosclerotic plaque injury

(2011) Béatrice Hechler et al.   THROMBOSIS AND HAEMOSTASIS

Impact of glycoprotein VI and platelet adhesion on atherosclerosis—A possible role of fibronectin

(2010) Andreas Bültmann et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

A 2-Step Mechanism of Arterial Thrombus Formation Induced by Human Atherosclerotic Plaques

(2010) Armin J. Reininger et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

GPVI and CLEC-2 in hemostasis and vascular integrity

(2010) S. P. WATSON et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

(2010) L. A. Honigberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Primary B Cell Immunodeficiencies: Comparisons and Contrasts

(2009) Mary Ellen Conley et al.   Annual Review of Immunology

Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation

(2009)   NEW ENGLAND JOURNAL OF MEDICINE

The immunoadhesin glycoprotein VI-Fc regulates arterial remodelling after mechanical injury in ApoE−/− mice

(2008) Tanja Schönberger et al.   CARDIOVASCULAR RESEARCH

Bleeding risks of combination vs. single antiplatelet therapy: a meta-analysis of 18 randomized trials comprising 129 314 patients

(2008) Victor L. Serebruany et al.   FUNDAMENTAL & CLINICAL PHARMACOLOGY

Complementary roles of platelets and coagulation in thrombus formation on plaques acutely ruptured by targeted ultrasound treatment: a novel intravital model

(2008) M. J. E. KUIJPERS et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS